Phase 2 N=64 A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
Parkinson's Disease
Primary: Maintenance Dose of the SPM962 — 0; 0; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=143 A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
Parkinson's Disease
Primary: Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters — 140; 122; 18; 9 participants
Phase 2 N=156 Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Urinary Bladder, Overactive
Primary: Change From Baseline in the Daily Average Number of Micturition (Urination) Episodes — 13.7; 12.2; 11.0; 10.6 Episodes
Phase 3 N=180 A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
Early Parkinson's Disease
Primary: Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3 — -8.4; -4.1 Scores on a scale — p=0.002
Phase 2 N=174 A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score — -10.1; -4.4 Scores on a scale
N/A N=1,716 Special Investigation in Patients With Crohn's Disease (All Patients Investigation)
Crohn's Disease
Primary: Number of Participants With Adverse Events (AEs) — 453; 147; 360; 96 participants
Phase 4 N=309 A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Rheumatoid Arthritis
Primary: Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24 — 4.11; 3.75 scores on a scale
Phase 3 N=236 Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis
Uremic Xerosis
Primary: Treatment Response of Xerosis — 71; 48 participants
N/A N=198 Developing and Evaluating Interventions to Reduce Inappropriate Prescribing of Antibiotics in Primary Care
Antibiotic Prescribing by GPs for URTI
Primary: Number of Simulated Scenarios Where an Antibiotic Was Not Prescribed — 5; 5; 4.2 scenarios
Phase 2 N=102 Open-label Study of Safety and Tolerability of Memantine in Children With Autism
Autism · Pediatric Autism
Primary: Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE) — 85 participants
Phase 4 N=14 ABRA Abdominal Closure System in Open Abdomen Management
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
Phase 3 N=198 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
Meningococcal Disease
Primary: Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination — 85; 74; 60; 83 Percentage of subjects
Phase 4 N=626 MAPS Trial: Matrix And Platinum Science
Intracranial Aneurysms
Primary: Target Aneurysm Recurrence (TAR) Defined as Clinically Relevant Recurrence Resulting in Target Aneurysm Reintervention, Rupture/Re-rupture and/or Death From an Unknown…
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 2 N=29 Clofarabine Bone Marrow Cytoreduction
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants